FDA Decision Affects Hims & Hers – Focus on Quarterly Results This Evening
Reading Time: 3 minutes
• Production of GLP-1 mimetics ends: With the end of the Wegovy supply shortage, Hims & Hers must halt production by May 2025 – a heavy blow for its lucrative weight loss segment. • Tension ahead of Q4 results: Despite a 25% drop in stock price, investors are hopeful for strong quarterly results and details on the future strategy in weight loss medications. The US Food and Drug Administration (FDA) announced on Friday, February 21, 2025, that the shortage of the popular weight loss drug Wegovy from Novo Nordisk has ended. This...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
